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Abstract 22	
 23	
We evaluated the effect of adjunctive intravenous immunoglobulin (IVIG) on mortality in 24	
clindamycin-treated streptococcal toxic shock syndrome patients using a meta-analysis. In 25	
association with IVIG, mortality fell from 33.7% to 15.7% (risk ratio 0.46, 95% confidence 26	
intervals 0.26-0.83, p=0.010) with remarkable consistency across the single randomised 27	
and four non-randomised studies. 28	
 29	
Brief report 30	
 31	
Streptococcal toxic shock syndrome (STSS) is a complication of invasive Streptococcus 32	
pyogenes infection (IGAS) characterised by hypotension and end-organ failure often with 33	
immunological manifestations such as rash [1]. Notwithstanding the formal case definition, 34	
it should be noted that shock in a patient with IGAS will almost always represent STSS [2]. 35	
Complicating IGAS in approximately 10% of cases, STSS is thought to be triggered in part 36	
by superantigens and other bacterial virulence factors. Mortality associated with STSS is 37	
substantial exceeding 25% within the first twenty-four hours in some studies [3]. In 38	
addition, STSS is associated with substantial morbidity with most cases requiring intensive 39	
care.  40	
 41	
Polyspecific intravenous immunoglobulin (IVIG) is recommended by some experts as an 42	
adjunctive treatment for STSS, not least because of laboratory data indicating potentially 43	
beneficial effects including neutralisation of superantigens and enhanced bacterial 44	
clearance [4]. However, the use of IVIG for STSS has been difficult to evaluate clinically; 45	
the only randomised controlled trial (RCT) was stopped early due to slow recruitment [5]. 46	
Although a small number of non-randomised studies have been reported, the interpretation 47	
of these data is complicated by the inherent risk of bias, the variable inclusion criteria and 48	
the inconsistent use of clindamycin, which is widely advocated as an adjunct to penicillin. 49	
We undertook a systematic review of randomised and non-randomised studies that 50	
evaluated the use of adjunctive IVIG in STSS. We then did a meta-analysis of the effect of 51	
IVIG on mortality in the subgroup of patients with STSS whose antibiotic therapy included 52	
clindamycin. 53	
 54	
We searched English language entries in MEDLINE and EMBASE since 1980 using the 55	
terms “streptococcus” OR “streptococcal” and “intravenous immunoglobulin” OR “ivig” 56	
(Supplementary Figure 1). We also searched reference lists of shortlisted articles. We 57	
included studies that evaluated the relationship between IVIG and mortality in patients with 58	
STSS prospectively identified using the consensus criteria [2]. We excluded studies that 59	
were retrospective and did not detail the use of clindamycin or did not define STSS. 60	
Eligibility assessment and data extraction were done unblinded by the first and second 61	
authors. We also assessed risk of bias using tools published by the Cochrane 62	
Collaboration. In addition, we contacted the authors of eligible studies including 63	
unpublished abstracts to request a breakdown of all results by use of clindamycin. Our 64	
primary measure of treatment effect was the risk ratio (RR) of death at 30 days calculated 65	
with its standard error for the subgroup of patients with STSS who received clindamycin. 66	
We then did a meta-analysis using a random effects model and assessed heterogeneity 67	
using the I2 statistic. All analyses were done using Stata 12.1 (StataCorp, Texas). 68	
 69	
The search, which was last updated on 31st December 2017, revealed 412 articles after 70	
removal of duplicates (Supplementary Figure 2). Fourteen articles were shortlisted of 71	
which one randomised [5] and four non-randomised studies [6-9] met the inclusion criteria 72	
(Supplementary Table 1 and Supplementary Table 2).  The included studies were 73	
undertaken between 1992 and 2009 in Northern Europe, Canada and Australia. The 74	
randomised study compared IVIG to placebo and the non-randomised studies compared 75	
IVIG to standard care. One of the non-randomised studies used historical controls [6] while 76	
the other three used concurrent patients who did not receive IVIG as controls [7-9]. Across 77	
all five studies, IVIG was administered to 70 and not administered to 95 of the STSS 78	
patients treated with clindamycin (Supplementary Table 3). Overall mortality was 26.1%, 79	
ranging between 14.3 and 40.5% in the individual studies. 80	
 81	
We found risk of bias across several domains in the non-randomised studies 82	
(Supplementary Table 4). In particular, we noted at least moderate risk of bias due to 83	
baseline differences between IVIG-treated cases and controls. Although adjusted analyses 84	
were reported, it is likely that some baseline confounding persisted, not least because the 85	
small sample sizes limited the utility of multivariate regression. Despite limiting our 86	
analyses to the subgroups treated with clindamycin, we expect some of this bias remained 87	
in our analyses. In addition, two of these studies collected some information 88	
retrospectively, using questionnaires, with the potential for selection bias. Furthermore, 89	
three of these studies provided no details of IVIG dosing, potentially introducing 90	
classification bias. Separately, a funnel plot of the four non-randomised studies – using all 91	
reported data rather than the subset analysed here – suggests the possibility of reporting 92	
bias, although interpreting the plot with so few studies is difficult (Supplementary Figure 3). 93	
In contrast, we found limited risk of bias in the randomised study (Supplementary Table 5).  94	
 95	
In all five studies, administration of IVIG in the clindamycin-treated subgroup was 96	
associated with lower mortality, although none reached statistical significance in isolation 97	
(Figure 1; Supplementary Table 6). However, in the pooled analysis, administration of IVIG 98	
was associated with a reduction in mortality from 33.7% to 15.7% (RR 0.46, 95% 99	
confidence intervals, CI, 0.26-0.83, p=0.010) with negligible heterogeneity (I2=0%). The 100	
pooled result of the non-randomised studies (RR 0.47, 95% CI 0.25-0.86) was remarkably 101	
consistent with the effect size estimate of the RCT (RR 0.42, 95% 0.05-3.28). 102	
 103	
This systematic review and meta-analysis provides evidence that administration of 104	
adjunctive IVIG to clindamycin-treated patients with STSS is associated with a statistically 105	
significant reduction in mortality. Crucially, our analysis disentangles the effects of 106	
clindamycin from those of IVIG, which has sometimes been problematic [6,7]. Our results 107	
therefore corroborate the findings of the Linnér et al. study [8], the largest of the three 108	
more recent non-randomised studies, which suggested both clindamycin and IVIG were 109	
beneficial. Moreover, by limiting the analysis to clindamycin-treated subgroups, we provide 110	
a more informative effect size estimate than those derived from the individual datasets. 111	
Overall our results imply that as many as one additional death could be prevented for 112	
every six clindamycin-treated patients with STSS administered IVIG.  113	
 114	
Three of the studies we excluded are worthy of further discussion not least because their 115	
main results appear to contradict our findings. The first prospectively assessed the efficacy 116	
of IVIG in patients with IGAS with or without STSS admitted to the ICU at four tertiary 117	
hospitals in Canada [10]. Unfortunately, the authors of this report were unable to provide 118	
us with the results for the subset of patients with STSS treated with clindamycin. Thus, 119	
while IVIG had no effect on mortality from IGAS overall, the impact of IVIG in the subset of 120	
patients with STSS remains unknown. The second retrospectively identified STSS patients 121	
admitted to tertiary paediatric hospitals in the USA using ICD-9 coded discharge 122	
diagnoses [11]. Accordingly, this study is highly likely to have included patients with 123	
diagnoses other than STSS, a group that would have been both less likely to receive IVIG 124	
and less likely to die than those with STSS. The third respectively identified patients with 125	
necrotising fasciitis and vasopressor-dependent shock from 121 hospitals in the USA [12]. 126	
In a propensity-matched analysis based on 322 patients, the authors found that IVIG had 127	
no effect on mortality. However, addition of data from 49 patients with coding for S. 128	
pyogenes and clindamycin (Supplementary Table 7) to our meta-analysis had a negligible 129	
effect on our results (Supplementary Figure 4).  130	
 131	
Our study has three main limitations. First, despite pooling five studies, our analysis 132	
remains small and consequently our effect size estimate lacks precision. Second, despite 133	
limiting the meta-analysis to the clindamycin-treated subgroup, there is a sizeable risk the 134	
baseline characteristics differed between those administered and not administered IVIG. 135	
For example, in the Linnér et al. study [8], there were differences at baseline in terms of 136	
age, co-morbidities and presence of necrotising fasciitis, all of which were associated with 137	
increased risk of death. Nonetheless, we predict IVIG would be administered more 138	
frequently to the most unwell patients, thereby introducing any bias towards a null effect. 139	
That said, while the similarity of the signal in the single RCT and four non-randomised 140	
studies is reassuring, it remains plausible that the reduction in mortality associated with 141	
IVIG in this analysis is due to confounding. Third, relatively limited information was 142	
available regarding the use antibiotics other than clindamycin. This issue could 143	
theoretically bias our results in favour of IVIG if certain potentially beneficial antibiotics 144	
including penicillin were used more often with IVIG. It is noteworthy, however, that the 145	
antibiotic regimen in the RCT was pre-specified [5] and all but one patient in the Linnér et 146	
al. study received a b-lactam agent [8]. Fourth, we were unable to address a number of 147	
outstanding questions including the optimum dosing and timing of IVIG. Ultimately, 148	
therefore, in the absence of sufficiently sized RCTs, a meta-analysis of observational 149	
studies may be the best means available to evaluate such an intervention. Looking 150	
forward, establishment of an international registry of STSS cases may provide more robust 151	
data to inform management of this devastating condition. 152	
 153	
In conclusion, our study helps address doubt surrounding the use of IVIG in STSS. It also 154	
highlights the utility of synthesising findings from small non-randomised studies in the 155	
absence of large-scale trials. Overall, given the high morbidity and mortality associated 156	
with STSS, we support the use of IVIG as an adjunctive treatment for STSS, a 157	
recommendation that applies to the vast majority of patients with IGAS complicated by 158	
shock.  159	
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Supplementary Figure 1. Search strategy  
 
 
Supplementary Figure 2. Flow diagram showing study selection 
 Supplementary Figure 3. Funnel plot for the non-randomised studies showing the 
unadjusted risk ratio for mortality with and without IVIG calculated from the full reported 
dataset (i.e. irrespective of clindamycin, GAS or STSS)  
 Supplementary Figure 4. Forest plot showing the estimated risk ratio for mortality with 
and without IVIG in clindamycin-treated STSS with the addition of data from the 
propensity-matched case-control analysis by Kadri et al. [12].  
Supplementary Table 1. Summary of the included studies 
Study Location Year Design Age range Outcome  Intervention Cases Controls Ref. 
Kaul et al. 
1999 
Canada 1992-
1995 
Non-randomised 
with historical 
controls  
Adults 
(mean 56.8 
years; range 
not reported) 
Mortality at 
30 days  
IVIG vs 
standard 
care 
GAS-associated 
STSS patients 
identified 
prospectively 
through 
surveillance treated 
with IVIG  
GAS-associated 
STSS patients 
identified 
prospectively 
through earlier 
surveillance not 
treated with IVIG  
[6] 
Darenberg et 
al. 2003 
Sweden, 
Norway, 
Finland, 
Netherlands 
1999-
2001 
Randomised 
double-blind, 
placebo-
controlled trial 
Adults (28-
83 years) 
Mortality at 
28 days  
IVIG vs 
placebo 
(equal vol. 
1% albumin) 
STSS patients 
enrolled on the 
basis of suspicion 
of GAS infection 
randomised to IVIG  
STSS patients 
enrolled on the 
basis of suspicion 
of GAS infection 
randomised to 
placebo 
[5] 
Carapetis et 
al. 2014 
Australia 2002-
2004 
Non-randomised 
with concurrent 
controls 
Adults and 
children (3-
88 years) 
Mortality at 
30 days 
IVIG vs 
standard 
care 
Severe IGAS 
patients identified 
prospectively 
through 
surveillance treated 
with IVIG 
Severe IGAS 
patients identified 
prospectively 
through 
surveillance not 
treated with IVIG 
[7] 
Linnér et al. 
2014 
Sweden 2002-
2004 
Non-randomised 
with concurrent 
controls 
Adults (31-
92 years) 
Mortality at 
28 days  
IVIG vs 
standard 
care 
GAS-associated 
STSS patients 
identified 
prospectively 
through 
surveillance treated 
with IVIG 
GAS-associated 
STSS patients 
identified 
prospectively 
through 
surveillance not 
treated with IVIG 
[8] 
Adalat et al. 
2014 
UK 2008-
2009 
Non-randomised 
with concurrent 
controls 
Children (0-
15 years) 
Mortality at 
28 days 
IVIG vs 
standard 
care 
GAS-associated 
STSS patients 
identified 
prospectively 
through 
surveillance treated 
with IVIG 
GAS-associated 
STSS patients 
identified 
prospectively 
through 
surveillance not 
treated with IVIG 
[9] 
Supplementary Table 2. Summary of the excluded studies 
Study Location Year Principal Reason(s) for Exclusion Total IGAS Proportion STSS Ref. 
Haywood et al. 
1999 
Canada 1995-
1997 
Less than 10 STSS cases 20 5/20 (25%) [13] 
Huang et al. 2001 Taiwan 1995-
2000 
Retrospective study  
 
76 12/76 (16%) [14] 
Norrby-Teglund et 
al. 2005 
 
Canada 1996-
2002 
Less than 10 STSS cases 
 
7 6/7 (86%) [15] 
Mehta et al. 2006 Canada 1992-
2002 
Subset data unavailable  62 34/62 (55%) [10] 
Aronoff & Mulla 
2008 
USA 1996-
2001 
Retrospective study  
Less than 10 STSS cases 
7 1/7 (14%) [16] 
Shah et al. 2009 USA 2003-
2007 
Retrospective study 
Consensus criteria not used 
192 192/192 (100%) [11] 
McViety et al. 
2014 
UK 2008-
2013 
Retrospective study 
No deaths in clindamycin treated cases 
23 17/23 (74%) [17] 
Chen et al. 2016 Australia 2003-
2014 
Retrospective study 
No deaths in clindamycin treated cases 
19 
 
19/19 (100%) [18] 
Kadri et al. 2016* USA 2010-
2014 
Retrospective study  
Consensus criteria not used 
228 228/228(100%) 
 
[12] 
*In total 50 of 228 (21.9%) patients with coding for GAS in the entire study were included in the propensity-matched analysis. 
 
   
Supplementary Table 3. Derivation of subgroup of interest from included studies 
Study Total IGAS Proportion STSS Proportion treated 
with clindamycin 
Proportion treated 
with clindamycin & 
IVIG  
(i.e. cases) 
Proportion treated 
with clindamycin & 
not IVIG  
(i.e. controls) 
Ref. 
Kaul et al. 1999* 53 53/53 (100%) 37/53 (37%) 20/37 (54%) 17/37 (46%) [6] 
Darenberg et al. 
2003 
18 18/18 (100%) 18/18 (100%) 8/18 (44%) 10/18 (56%) [5] 
Carapetis et al. 
2014† 
84 49/84 (58%) 37/49 (76%) 13/37 (35%) 24/37 (65%) [7] 
Linnér et al. 2014 746 67/746 (9%) 52/67 (78%) 21/52 (40%) 31/52 (60%) [8] 
Adalat et al. 
2014 
29 29/29 (100%) 21/29 (72%) 8/21 (38%) 13/21 (62%) [9] 
*Data on clindamycin not available for one control who died. 
†Includes severe IGAS patients with and without STSS; 49 classified as having STSS. 
 
  
Supplementary Table 4. Risk of bias in the non-randomised studies [19] 
Study Confounding 
at baseline* 
Bias in 
selection 
Bias in 
classification 
Bias in 
deviations 
Bias in 
missingness 
Bias in 
measurement 
Bias in 
reporting 
Ref. 
Kaul et al. 1999 Moderate Low Low Low Low Low Low [6] 
Carapetis et al. 
2014 
Moderate Low Moderate Low Low Low Moderate [7] 
Linnér et al. 2014 Moderate Low Moderate Low Low Low Low [8] 
Adalat et al. 
2014 
Serious Low Moderate Low Low Low Low [9] 
*Data included in the meta-analysis was corrected for confounding only by limiting the analysis to patients treated with clindamycin. 
 
 
 
 
 
Supplementary Table 5. Risk of bias in the randomized control trial [20] 
Study Bias in 
selection 
Bias in 
performance 
Bias in 
detection 
Bias in attrition Bias in 
reporting 
Other bias Ref. 
Darenberg et al. 
2003 
Unclear* 
 
Low  Low Low Low Stopped early [5] 
*Neither random sequence nor allocation concealment reported. 
 
 
 
  
Supplementary Table 6. Summary results of included studies 
Study Mortality in full dataset  
(i.e. irrespective of clindamycin, GAS or STSS) 
Mortality in subgroup of interest 
(i.e. clindamycin-treated STSS)  
Ref. 
Cases Controls Cases Controls  
Kaul et al. 1999 7/21 (33%) 21/32 (66%) 6/20 (30%) 9/17 (53%) [6] 
Darenberg et al. 
2003 
1/10 (10%) 4/11 (36%) 1/8 (13%) 3/10 (30%) [5] 
Carapetis et al. 
2014† 
1/14 (7%) 19/70 (27%) 1/13 (8%) 6/24 (25%) [7] 
Linnér et al. 2014 3/23 (13%) 22/44 (50%) 3/21 (14%) 11/31 (35%) [8] 
Adalat et al. 
2014 
0/8 (0%) 10/41 (24%) 0/8 (0%) 3/13 (23%) [9] 
 
Supplementary Table 7. Derivation of subgroup of interest from the propensity-matched case-control analysis in Kadri et al. [12] 
Study Total IGAS Proportion STSS Proportion treated 
with clindamycin 
Proportion treated 
with clindamycin & 
IVIG  
(i.e. cases) 
Proportion treated 
with clindamycin & 
not IVIG  
(i.e. controls) 
Ref. 
Kadri et al. 2016 50* 
 
50/50 (100%)† 
 
49/50 (100%) 26/49 (53%) 23/49 (47%) [12] 
*In total 50 of 228 (21.9%) patients with coding for GAS in the entire study were included in the propensity-matched analysis. 
†Only 25 of the 49 patients with coding for GAS and clindamycin in the propensity-matched analysis also had coding for toxic shock 
syndrome. For the purposes of this analysis, however, we presumed all 49 would have met diagnostic criteria for STSS based on the 
combination of GAS, vasopressor-dependent shock and necrotising infection.  
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